Loading...
•
Mar 31, 2020
Integra LifeSciences Q1 2020 Earnings Report
Reported a decrease in revenue and earnings due to the impact of COVID-19.
Key Takeaways
Integra LifeSciences reported a decrease in revenue by 1.5% and a decline in GAAP earnings per diluted share from $0.38 to $0.11 compared to the prior year, largely due to the negative impact of COVID-19 which led to deferral of non-emergent surgical procedures.
Reported revenues were $354.3 million, a decrease of (1.5)% on a reported basis and (0.1)% on an organic basis, compared to the prior year.
GAAP earnings per diluted share were $0.11, compared to $0.38 in the first quarter of 2019.
Adjusted earnings per diluted share were $0.48, compared to $0.65 in the prior year.
The company estimates the revenue impact from the decline in surgical procedures related to COVID-19 during the second half of March to be between $20 and $25 million.
Revenue by Segment
Forward Guidance
Given the existing uncertainty related to COVID-19, the Company’s guidance for the full-year 2020, issued on February 19, 2020, remains withdrawn as announced on April 7, 2020.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...